ZyVersa Therapeutics, Inc. (ZVSA): auditor change — ZyVersa Therapeutics dismisses Ernst & Young, appoints Marcum as auditor

ZyVersa Therapeutics, Inc.

Dismissed EY as independent auditor on Dec 22, 2023; EY served from 2019 through Q3 2023 and interim period.
EY's audit reports for FY2022 and FY2021 included going-concern explanatory paragraph about substantial doubt.
No disagreements with EY; material weaknesses in internal controls over complex transactions were disclosed in 2022 10-K.
Audit Committee appointed Marcum LLP as new independent registered public accounting firm for FY2023.
No prior consultations with Marcum regarding accounting principles or audit opinions.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

ZyVersa Therapeutics, Inc. engaged Marcum LLP as its auditor.

Action: engagement
Auditor: Marcum LLP

Exact text from the filing

On December 22, 2023, the Audit Committee appointed Marcum as the Company’s new independent registered public accounting firm commencing with the Company’s fiscal year ending December 31, 2023.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

ZyVersa Therapeutics, Inc. dismissed Ernst & Young LLP as its auditor.

Action: dismissal
Auditor: Ernst & Young LLP
Successor: Marcum LLP

Exact text from the filing

dismissed Ernst & Young LLP ("EY") as the Company’s independent registered public accounting firm.

View on SEC.gov

Browse all auditor changes →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-045948

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.